ChemicalBook
Chinese english Germany Japanese Korea

Amiodaron Produkt Beschreibung

Amiodarone Struktur
1951-25-3
CAS-Nr.
1951-25-3
Bezeichnung:
Amiodaron
Englisch Name:
Amiodarone
Synonyma:
Ancaron;Atlansil;Sedacoron;AMidorone;Amiodarons;Sedacorone;amiodarona;AMIODARONE;Tranquerone;Amiodarone Base
CBNumber:
CB5310616
Summenformel:
C25H29I2NO3
Molgewicht:
645.31
MOL-Datei:
1951-25-3.mol

Amiodaron Eigenschaften

Dichte
1.5730 (estimate)
storage temp. 
2-8°C
pka
6.56(at 25℃)
Stabilität:
Stable. Incompatible with strong oxidizing agents.
CAS Datenbank
1951-25-3(CAS DataBase Reference)

Sicherheit

Kennzeichnung gefährlicher Xn
R-Sätze: 20/21/22
S-Sätze: 36
WGK Germany  3
RTECS-Nr. OB1361000

Amiodaron Chemische Eigenschaften,Einsatz,Produktion Methoden

R-Sätze Betriebsanweisung:

R20/21/22:Gesundheitsschädlich beim Einatmen,Verschlucken und Berührung mit der Haut.

S-Sätze Betriebsanweisung:

S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.

Verwenden

antibacterial

Definition

ChEBI: A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.

Trademarks

Cordarone (Wyeth-Ayerst).

Biologische Funktion

Amiodarone (Cordarone) is an iodine-containing benzofuran derivative identified as a class III agent because it predominantly prolongs action potentials. Amiodarone also blocks sodium and calcium channels and is a noncompetitive β-receptor blocker.Amiodarone is effective for the treatment of most arrhythmias. Toxicity associated with amiodarone has led the U. S. Food and Drug Administration (FDA) to recommend that it be reserved for use in patients with life-threatening arrhythmias.

Allgemeine Beschreibung

Amiodarone, 2-butyl-3-benzofuranyl-4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl ketone (Cordarone),was introduced as an antianginal agent. It has very pronouncedclass III action and is especially effective in maintainingsinus rhythm in patients who have been treated bydirect current shock for atrial fibrillation. Like class IIIantiarrhythmic drugs, amiodarone lengthens the effective refractoryperiod by prolonging the action potential duration inall myocardial tissues. Amiodarone is eliminated very slowlyfrom the body, with a half-life of about 25 to 30 days after oraldoses. Although the drug has a broad spectrum of antiarrhythmicactivity, its main limitation is a slow onset of action.Drug action may not be initiated for several days, and thepeak effect may not be obtained for several weeks.

Clinical Use

Amiodarone has adverse effects involving many differentorgan systems. It also inhibits metabolism of drugscleared by oxidative microsomal enzymes. It contains iodinein its molecular structure and, as a result, has an effecton thyroid hormones. Hypothyroidism occurs in up to 11%of patients receiving amiodarone. The principal effect isthe inhibition of peripheral conversion of T4 to T3. Serumreverse T3 (rT3) is increased as a function of the dose as wellas the length of amiodarone therapy. As a result, rT3 levelshave been used as a guide for judging adequacy of amiodaronetherapy and predicting toxicity.

Nebenwirkungen

Amiodarone’s most significant adverse effects include hepatitis, exacerbation of arrhythmias, worsening of congestive heart failure, thyroid dysfunction, and pulmonary fibrosis. Pulmonary fibrosis is frequently fatal and may not be reversed with discontinuation of the drug. Interestingly, despite significant prolongation of the QT interval, the risk of torsades de pointes is relatively low. Patients with underlying sinus node dysfunction tend to have significant worsening of nodal function, frequently requiring pacemaker implantation. Corneal microdeposits develop in most adults receiving amiodarone. As many as 10% of patients complain of halos or blurred vision. The corneal microdeposits are reversible with stoppage of the drug.
Photosensitization occurs in 10% of patients. With continued treatment, the skin assumes a blue-gray coloration. The risk is increased in patients of fair complexion. The discoloration of the skin regresses slowly, if at all, after discontinuation of amiodarone.
Amiodarone inhibits the peripheral and possibly intrapituitary conversion of thyroxine (T4) to triiodothyronine (T3) by inhibiting 5 -deiodination. The serum concentration of T4 is increased by a decrease in its clearance, and thyroid synthesis is increased by a reduced suppression of the pituitary thyrotropin T3. The concentration of T3 in the serum decreases, and reverse T3 appears in increased amounts.Despite these changes, most patients appear to be maintained in an euthyroid state. Manifestations of both hypothyroidism and hyperthyroidism have been reported.
Tremors of the hands and sleep disturbances in the form of vivid dreams, nightmares, and insomnia have been reported in association with the use of amiodarone. Ataxia, staggering, and impaired walking have been noted. Peripheral sensory and motor neuropathy or severe proximal muscle weakness develops infrequently. Both neuropathic and myopathic changes are observed on biopsy. Neurological symptoms resolve or improve within several weeks of dosage reduction.

Sicherheitsprofil

Poison by intravenous and intraperitoneal routes. Human systemic effects by ingestion: photosensitivity of the skin. A flammable liquid. When heated to decomposition it emits very toxic fumes of Iand NO,. A coronary vasoddator

Arzneimittelwechselwirkung

Amiodarone increases the hypoprothrombinemic response to warfarin (an oral anticoagulant) by reducing its metabolism. Patients receiving digoxin may undergo an increase in serum digoxin concentrations when amiodarone is added to the treatment regimen. Amiodarone interferes with hepatic and renal elimination of flecainide, phenytoin, and quinidine.

Vorsichtsmaßnahmen

Amiodarone is contraindicated in patients with sick sinus syndrome and may cause severe bradycardia and secondand third-degree atrioventricular block. Amiodarone crosses the placenta and will affect the fetus, as evidenced by bradycardia and thyroid abnormalities. The drug is secreted in breast milk.

Amiodaron Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


Amiodaron Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 63)Lieferanten
Firmenname Telefon Fax E-Mail Land Produktkatalog Edge Rate
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21753 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32447 55
Chemwill Asia Co.,Ltd.
86-21-51086038
86-21-51861608 chemwill_asia@126.com;sales@chemwill.com;chemwill@hotmail.com;chemwill@gmail.com CHINA 23964 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254
027-59599243 sales@jushengtech.com CHINA 28237 58
BOC Sciences
1-631-619-7922
1-631-614-7828 inquiry@bocsci.com United States 20115 58
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96815 76
BePharm Ltd 4001-647-117; 021-61629020
021-61629029 product@bidepharmatech.com China 24689 61
Chemfun Medical Technology(Shanghai) Co., Ltd. 021-67220633 & 021-37212706
+86-21-67220638 chemfun@chemfun.net China 21812 59
Syntechem Co.,Ltd Please Email
E-Mail Inquiry info@syntechem.com China 13010 57

1951-25-3(Amiodaron)Verwandte Suche:


  • (2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diidophenyl)methanone
  • 2-butyl-3-(3,5-diiodo-4-(2-diethylaminoethoxy)benzoyl)benzofuran
  • 2-butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)benzoyl)benzofuran
  • 2-butyl-3-(3,5-diiodo-4-(beta-diethylaminoethoxy)-benzoyl)benzofuran
  • 2-butyl-3-(4’-beta-n-diethylaminoethoxy-3’,5’-diiodobenzoyl)benzofuran
  • 2-butyl-3-benzofuranylp-((2-diethylamino)ethoxy)-m,m-diiodophenylketone
  • 2-n-butyl-3’,5’-diiodo-4’-n-diethylaminoethoxy-3-benzoylbenzofuran
  • Amiodarone Base
  • Amiodarons
  • Methanone, (2-butyl-3-benzofuranyl)4-2-(diethylamino)ethoxy-3,5-diiodophenyl-
  • Atlansil
  • Tranquerone
  • (2-Butylbenzofuran-3-yl)[4-[2-(diethylamino)ethoxy]-3,5-diiodophenyl]methanone
  • Sedacoron
  • Sedacorone
  • (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodophenyl]methanone
  • (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodo-phenyl]methanone
  • (2-butylbenzofuran-3-yl)-[4-(2-diethylaminoethyloxy)-3,5-diiodo-phenyl]methanone
  • AMidorone
  • Aqueous aMiodarone
  • Ancaron
  • amiodarona
  • ketone,2-butyl-3-benzofuranyl4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl
  • methanone,(2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophen
  • AMIODARONE
  • 2-BUTYL-3-BENZOFURANYL 4-[2-(DIETHYLAMINO)-ETHOXY]-3,5-DIIODOPHENYL KETONE
  • 1951-25-3
  • C25H29I2NO3
  • Voltage-gated Ion Channels
  • Inhibitors and Activators
  • Ion Channels
  • Cell Signaling and Neuroscience
  • Cell Biology
  • Calcium Channel Modulators
  • BioChemical
  • CEFOMONIL
Copyright 2019 © ChemicalBook. All rights reserved